Objectives: Off-label medication use for treating cognitive impairments and neuropsychiatric symptoms occurs in frontotemporal dementia (FTD) and Alzheimer disease (AD). We compared the use of cognitive and psychiatric medications in FTD and AD and evaluated the relationship between neuropsychiatric symptoms and medication use.
(Alzheimer Dis Assoc Disord 2014; 28:182-189) A lzheimer disease (AD) and frontotemporal dementia (FTD) are common causes of dementia that are associated with considerable morbidity and mortality, as well as caregiver distress. FTD is the most common cause of dementia in patients under the age of 60 [1] [2] [3] ; however, there are no FDA-approved medications for treatment of FTD. 4, 5 In contrast, modestly effective cognitive treatments including acetylcholinesterase inhibitors (AchI; donepezil, galantamine, and rivastigmine) and the NMDA-receptor antagonist, memantine, 6 are approved for the symptomatic treatment of AD. 6 Patients with AD and FTD usually display different symptoms, with AD classically presenting with a slowly progressive episodic memory deficit. Deficits in cholinergic neurotransmission are believed to be central to the development of AD, 7 and the efficacy of AChI for stabilizing cognitive function has been directly related to central effects on acetylcholinesterase function. 8, 9 However, patients with AD can also often develop behavioral impairments, such as agitation and irritability; often, these are the most troublesome symptoms for the caregivers. 10, 11 There are no FDA-approved drugs for behavioral and psychological symptoms observed in any type of dementia, but there is often off-label use. There is some evidence that donepezil and memantine have some benefit on behavioral and psychological symptoms observed in AD 11, 12 but often psychiatric medications including antipsychotics, antidepressants, and anxiolytics are used off-label to treat behavioral symptoms at all levels of disease severity. 13, 14 In FTD syndromes, behavioral and neuropsychiatric symptoms feature prominently. In behavioral variant FTD (bvFTD), the most common of the FTD syndromes, the earliest and the most conspicuous symptoms involve behavioral abnormalities that cause significant impairment and caregiver burden. [15] [16] [17] [18] [19] There are no FDA-approved drugs for these symptoms and physicians routinely prescribe off-label AChIs and memantine, 20, 21 although now both AChI and memantine have been reported to worsen behavior in bvFTD patients. 22, 23 Selective serotonin reuptake inhibitors and antipsychotic medications are also commonly used in bvFTD to target behavioral abnormalities, although randomized controlled trials are scarce to support their efficacy. 24 We previously compared the use of FDA-approved medications for AD and other psychiatric medications in AD and FTD in the State of California Alzheimer's Disease Centers, as well as a handful of other research centers involved in a longitudinal natural history study of FTD. 20 We found frequent off-label use of both AD and psychiatric medications in both AD and bvFTD; however, the study was limited by the heterogenous nature of the data sources, precluding the identification of potential factors accounting for such medication use. The aim of the present study was therefore to compare the use of cognitive and psychiatric medication and to identify demographic and neuropsychiatric factors associated with use of each type of medication in 2 patient groups that can have overlapping signs and symptoms: bvFTD and AD. We sought to test the hypothesis that use of both cognitive (donepezil, rivastigmine, galantamine, and memantine) and psychiatric medications (antidepressants, antipsychotics, anxiolytics, and mood stabilizers) would be associated with specific neuropsychiatric symptoms for which the medications were initially approved, irrespective of the associated dementia syndrome.
METHODS
Data consisted of variables from a Uniform Data Set collected from >30 Alzheimer's disease centers (ADC) throughout the United States and cataloged at the National Alzheimer's Coordinating Center (NACC). A full description of the NACC data set has been previously provided. 25, 26 ADCs are National Institute on Aging-funded centers that enroll patients by self-referral or referral from a community health care provider. Many are university-affiliated memory disorders clinics in urban settings. These centers have been collecting data on their patients from 1984 to 2010, and the NACC has been a central repository since 1999.
PATIENTS
The study cohort consisted of 3958 [3638 AD (79%) and 320 FTD (6%)] participants who had a diagnosis of probable AD according to the National Institute of Neurological Diseases and Stroke-Alzheimer's Disease and Related Disorders Association criteria or its equivalent 27 or probable bvFTD according to Neary criteria 28 at the initial visit. The data were collected between September 2005 and December 2009. In addition to a diagnosis of probable AD or bvFTD, cases were included only if they had medication use data, a Neuropsychiatric Inventory (NPI) score, 29 and all of the following data: vascular disease, race, disease duration, education, age, sex, psychiatric disease, and Clinical Dementia Rating sum of boxes score. Patients with a history of stroke or traumatic brain injury were excluded.
Variables Analyzed
The main predictor variables analyzed were the presence or absence of each of the following NPI symptoms: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, elation, disinhibition, aberrant motor behavior, nighttime behavior disturbances, and appetite and eating abnormalities. 29 The following variables were also included as predictors: presence or absence of history of psychiatric disease and vascular disease. Psychiatric disease included past or recent: anxiety disorder, depression, obsessive compulsive disorder, posttraumatic stress disorder, psychosis/schizophrenia/hallucination, bipolar, attention deficit hyperactivity disorder, and substance abuse. Vascular disease included past and/or recent: heart attack or cardiac arrest, atrial fibrillation, angio/endarectomy/stent, bypass, pacemaker, congestive heart failure, transient ischemic attack, smoker, hypertension, hypercholesterolemia, vitamin B12 deficiency, and diabetes. The original Clinical Dementia Rating sum of boxes (CDR-SB) 30 assesses the overall level of disease severity, and CDR-SB scores are useful for comparing disease severity between AD and FTD. 31 Additional predictor variables included: age, sex, race, education level, and disease duration. Age was calculated using the patients' date of birth and the date of the visit. Race was coded as white (Caucasian) or nonwhite (African American, Asian/Pacific Islander, Native American, Hispanic/Latino, others, and unknown) for the baseline characteristics analysis.
The outcome variables analyzed included cognitive medications and 15 other psychoactive medications (either over-the-counter or prescription) being used at the initial visit. These were recorded based on Multum drug codes. The cognitive medications analyzed were: memantine and AChI donepezil separately and then as a group with rivastigmine, galantamine, and memantine.
Psychiatric medications were categorized as antipsychotic, mood stabilizer, antidepressant, and anxiolytic medications. Use of the following antipsychotic agents was recorded: promethazine, risperidone, olanzapine, quetiapine, haloperidol, clozapine, prochlorperazine, aripiprazole, and perphenazine. Mood stabilizers included: carbamazepine, valproic acid, lithium, or lamotrigine. Antidepressants included: citalopram, sertraline, mirtazapine, trazodone, paroxetine, venlafaxine, maprotiline, amitriptyline, fluoxetine, dulozetine, nortriptyline, doxepin, clomipramine, fluvoxamine, escitalopram, and bupropion. Anxiolytic medications consisted of lorazepam, clonazepam, alprazolam, temazepam, zolpidem, eszopiclone, doxylamine, flurazepam, midazolam, phenobarbital, triazolam, chlordiazepoxide, oxazepam, buspirone, diphenhydramine, hydroxyzine, meprobamate, and ramelteon.
Statistical Analysis
The objective of the study was to compare neuropsychiatric symptoms and medication usage in AD and FTD and determine any interaction between the symptoms and medication. Two-sample student t tests were used to compare demographic variables (age, disease duration, and years of education) between AD and FTD patients. w 2 tests were used to compare the categorical variables [sex, race, comorbidities (psychiatric and vascular), cognitive and psychiatric medication use, and NPI variables] between AD and FTD patients.
We fit binary logistic regression models separately for AD and FTD patients to evaluate the relationship between medication usage and NPI, correcting for vascular disease, race, disease duration, education, age, sex, psychiatric disease, and CDR sum of boxes.
We included random center effects in the logistic regression models to accommodate potential correlation of responses within centers. Analyses were conducted using SPSS (version 17.0).
RESULTS
Demographics and other descriptive variables for the FTD group as compared with the AD group are shown in Table 1 . The FTD patients were younger, had a higher proportion of whites, and were more highly educated (P < 0.001) than the AD patients. The FTD group had higher CDR sum of boxes, as well as CDR global scores, indicating greater disease severity. The AD group had a higher proportion of female individuals compared with the FTD group (P < 0.001). Although vascular risk factors were slightly more prevalent in the AD group, this may not be clinically significantly different (86% vs. 81%, P = 0.04).
Consistent with the early predominance of behavioral symptoms in this disorder, history of psychiatric disease was more common in the FTD group (56% vs. 46%, P = 0.002). In addition, neuropsychiatric abnormalities including agitation, anxiety, elation, apathy, disinhibition, irritability, motor disturbances, nighttime behaviors, and appetite changes assessed using the NPI were more prevalent in FTD than in AD (Table 1 ). There was no difference in prevalence of delusions, hallucinations, or depression between the 2 groups.
Medication Use
Use of cognitive medications approved by the FDA for treatment of AD was more common in the AD group compared with the FTD group ( Table 2 ). The opposite was true for psychiatric medications, as there was greater use in the FTD group (Table 2 ). In the AD group, the most frequently used cognitive medication was donepezil followed by memantine, whereas the opposite was observed in the FTD group, with greater usage of memantine compared with donepezil. Fifty-six percent of AD patients as compared with 26% of FTD patients took donepezil, whereas 43% of AD subjects versus 33% of FTD subjects took memantine. Use of each class of psychiatric medication (antidepressants, antipsychotics, anxiolytics, or mood stabilizers) was more common in the FTD group than the AD group.
In the multivariate model controlling for vascular disease, race, disease duration, education, age, sex, history of psychiatric disease and disease severity (CDR-SB) variables, the type of dementia predicted the use of cognitive medications (as a group), as well as donepezil and memantine individually. When controlled for these variables, the model indicated that cognitive medications were more commonly used by AD patients compared with FTD patients (P < 0.001), and the probability of FTD patients being on cognitive medications was less compared with AD patients ( Table 2 ). Patients with FTD had a higher probability of being on psychiatric medications as a group, as well as antidepressants, antipsychotics, anxiolytics, and mood stabilizers individually, compared with patients with AD ( Table 2 ).
Predictors of Specific Medication Use in FTD
To identify neuropsychiatric symptoms and other factors associated with the use of cognitive and psychiatric medications in FTD, we used binary logistic regression analysis in AD and FTD groups separately with models that included disease severity (CDR sum of boxes), NPI, the presence of vascular disease, disease duration, as well as demographic variables (Figs. 1A, B ; Table 3 ).
Cognitive Medications
In FTD, cognitive medication use was most strongly associated with the presence of elevated elation scores on the NPI [odds ratio (OR) 2.38; 95% confidence interval (CI), 1.21-4.70; P = 0.012].
Donepezil
There were no statistically significant associations with donepezil use.
Memantine
Memantine use was associated with higher levels of education (OR 1.14; 95% CI, 1.04-1.25; P = 0.004) and greater disease severity (higher CDR-SB; OR 1.07; 95% CI, 1.02-1.14; P = 0.011). FTD patients were less likely to be on memantine if they were female, (OR 0.56; 95% CI, 0.32-0.95; P = 0.031), or had some NPI disinhibition (OR 0.53; 95% CI, 0.30-0.95; P = 0.032).
Psychiatric Medication
Having a history of psychiatric disease was associated with higher probability of any psychiatric medication use (OR 4.47; 95% CI, 2.49-8.05; P < 0.001), whereas psychiatric medication use was lower in patients with elevated irritability on the NPI (OR 0.53; 95% CI, 0.29-0.97; P = 0.039). 
Antidepressants
Use of the most commonly prescribed type of psychiatric medication, antidepressants, was also associated with a history of psychiatric disease (OR 4.14; 95% CI, 2.41-7.12; P < 0.001). The odds of taking an antidepressant were lower if irritability was present on the NPI (OR 0.51; 95% CI, 0.29-0.91; P = 0.022).
Antipsychotic Medications
Antipsychotic medication use was associated with greater disease severity as indicated by higher CDR-SB scores (OR 1.21; 95% CI, 1.1-1.3; P < 0.001) but was less common in individuals with elevated elation (OR 0.22; 95% CI, 0.05-0.99; P = 0.048) or apathy scores on the NPI (OR 0.23; 95% CI, 0.10-0.77; P = 0.014).
Mood Stabilizers
Mood stabilizer use was associated with FTD patients' age; younger patients were less likely to be on mood stabilizers (OR 0.89; 95% CI, 0.81-0.97; P = 0.01). The odds of mood stabilizer use were higher if they had appetite changes (OR 5.37; 95% CI, 1.03-27.9; P = 0.046) but lower with nighttime behaviors on the NPI (OR 0.145, 95% CI, 0.02-0.90; P = 0.038).
Anxiolytics
There were no statistically significant associations with anxiolytic use.
Prediction of Medication Use in AD

Cognitive Medications
In AD, we found that demographic variables were most predictive of medication use. The odds of taking any cognitive medication were higher if the patients were white (OR 1.78; 95% CI, 1.44-2.20; P < 0.001), had a longer disease duration (OR 1.08; 95% CI, 1.05-1.11; P < 0.001), were more educated (OR 1.04; 95% CI, 1.01-1.07; P < 0.001), had more severe disease (higher CDR-SB; OR 1.07; 95% CI, 1.04-1.10; P < 0.001), or were male (OR 1.23; 95% CI, 1.034-1.46; P = 0.019). The odds of being on cognitive medication were lower if they displayed elevated depression on the NPI (OR 0.90; 95% CI, 0.66-0.98; P = 0.027) or were older (OR 0.97; 95% CI, 0.96-0.98; P < 0.001).
Donepezil
Donepezil use was associated with the presence of disinhibition (OR 1.24; 95% CI, 1.03-1.49; P = 0.024) and irritability on the NPI (OR 1.18; 95% CI, 1.00-1.38; P = 0.044). AD patients were less likely to take donepezil if they had vascular risk factors (OR 0.82; 95% CI, 0.67-0.99; P = 0.043), were younger (OR 0.98; 95% CI, 0.97-0.99; P < 0.001), or had evidence of depression on the NPI (OR 0.76; 95% CI, 0.65-0.89; P = 0.001).
Memantine
The odds of taking memantine were greater if subjects were white (OR 2.17; 95% CI, 1.76-2.68; P < 0.001), had a longer disease duration (OR 1.03; 95% CI, 1.00-1.05; P = 0.017), were more educated (OR 1.05; 95% CI, 1.03-1.07; P < 0.001), or had more severe disease (CDR-SB; OR 1.12; 95% CI, 1.09-1.14; P < 0.001). The odds of taking memantine were lower with higher NPI irritability scores (OR 0.84; 95% CI, 0.71-0.99; P = 0.041) and increasing age (OR 0.98; 95% CI, 0.97-0.98; P < 0.001).
Psychiatric Medications
The model also predicted psychiatric medication use in AD. The odds of taking a psychiatric medication were greater if patients had psychiatric disease (OR 9.71; 95% CI, 8.17-11.5; P < 0.001), were white (OR 1.53; 95% CI, 1.22-1.91; P < 0.001), had longer disease duration (OR 1.04; 95% CI, 1.01-1.07; P = 0.002), were younger (OR 0.98; 95% CI, 0.98-0.99; P < 0.001), had greater disease severity (OR 1.05; 95% CI, 1.03-1.07; P < 0.001), were disinhibited (OR 1.33; 95% CI, 1.07-1.64; P = 0.009), or anxious (OR 1.24; 95% CI, 1.04-1.48; P = 0.016).
Psychiatric medications were used in 21% of patients with AD without a psychiatric diagnosis, whereas 28% of patients with a psychiatric diagnosis were not treated with a psychiatric medication.
Antidepressants
The odds of being on an antidepressant were greatest if AD patients had a history of psychiatric disease (OR 11.50; 95% CI, 9.61-13.75; P < 0.001) and were also higher if they were white (OR 1.84; 95% CI, 1.45-2.33; P < 0.001), had vascular risk factors (OR 1.32; 95% CI, 1.04-1.67; P < 0.001), had longer disease duration (OR 1.03; 95% CI, 1.01-1.06; P = 0.009), were younger (OR 0.98; 95% CI, 0.97-0.99; P < 0.001), had greater disease severity (CDR-SB; OR 1.03; 95% CI, 1.01-1.06; P = 0.004), or displayed disinhibition on the NPI (OR 1.38; 95% CI, 1.11-1.72; P = 0.004). Alzheimer Dis Assoc Disord Volume 28, Number 2, April-June 2014
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Antipsychotics Medications
Antipsychotic medication use was associated with greater disease severity (higher CDR-SB; OR 1.19; 95% CI, 1.15-1.24; P < 0.001), psychiatric disease, (OR 1.56; 95% CI, 1.08-2.26; P = 0.019), hallucinations (OR 1.58; 95% CI, 1.03-2.42; P = 0.035), or apathy on the NPI (OR 1.48; 95% CI, 1.03-2.12; P = 0.035). Antipsychotic use was less common in individuals with elevated 
Mood Stabilizer
The odds of being on a mood stabilizer were higher with greater disease severity (CDR-SB; OR 1.19; 95% CI, 1.00-1.24; P = 0.039) or the presence of delusions (OR 3.86; 95% CI, 1.24-12.0; P = 0.020) and lower if subjects were white (OR 0.33; 95% CI, 0.11-0.99; P < 0.047).
Anxiolytics
The odds of being on an anxiolytic were higher if a patient had a history of psychiatric disease, (OR 2.47; 95% CI, 1.87-3.27; P < 0.001), was anxious (OR 1.52; 95% CI, 1.16-1.98; P = 0.002), or displayed abnormal nighttime behaviors, (OR 1.34; 95% CI, 1.02-1.76; P = 0.039). The odds of anxiolytic use were lower in individuals who were apathetic (OR 0.62; 95% CI, 0.47-0.81; P < 0.001).
DISCUSSION
We found that more than half of all FTD patients at specialized NIH-designated dementia research centers take cognitive medications approved for the treatment of AD, despite no evidence of efficacy from randomized placebocontrolled clinical trials. The only double-blind, placebocontrolled clinical trial of a cholinesterase inhibitor in FTD showed no clear benefit. 32 An open-label study of donepezil in 12 patients with FTD found that caregivers of the treated patients endorsed a higher level of disinhibition and compulsiveness that reversed upon discontinuation of donepezil. 22 Recently, memantine too has been shown to be of no benefit in FTD. 23 As expected, a higher percentage of AD patients took cognitive medications. Although none of the demographic or neuropsychiatric variables examined were associated with cognitive medication use in FTD, in AD race, years of education and disease severity were strongly associated with cognitive medication use.
Psychiatric medications, both antipsychotics and antidepressants, were more commonly used in FTD than in AD, despite delusions, hallucinations, and depression being similarly prevalent in the 2 groups. In both disorders, the recent or past history of psychiatric disease was the strongest predictor of psychiatric medication as a group and antidepressant use, whereas greater disease severity was associated with antipsychotic medication use. It is unclear whether psychiatric symptoms were the presenting feature of the dementia and therefore misdiagnosed and treated with psychiatric medications or alternatively, psychiatric medications were prescribed to target psychiatric and behavioral symptoms that arise later in the course of dementia. The presence of these psychiatric and behavioral symptoms despite taking psychiatric medications indicates the ineffectiveness of the medications and warrants further investigation.
Consistent with previous studies, we found that neuropsychiatric abnormalities as measured by the NPI were more common in FTD than in AD. [33] [34] [35] However, AD patients also displayed frequent neuropsychiatric abnormalities including agitation in 35% of patients, apathy in 44%, disinhibition in 20%, and irritability in 39%, yet such symptoms were less frequently associated with psychiatric medication use than in FTD. Because neuropsychiatric symptom severity was not included in our analyses, it is possible that the more frequent use of psychiatric medications in FTD reflected greater severity of symptoms. 
Medication Class
Medication FTD AD
A notable finding from this study was the lack of consistent relationships between medication use and neuropsychiatric symptoms across the 2 illnesses. For example, the presence of apathy was associated with a higher probability of being on an antipsychotic in AD but a lower probability of antipsychotic use in FTD. Disinhibition was associated with increased odds of taking donepezil or an antidepressant in AD but decreased probability of taking an antipsychotic. However, in FTD, the presence of disinhibition was associated with decreased odds of memantine use. These findings suggest that our analyses identified neuropsychiatric variables that: (1) may have provided a rationale for prescription of different medications, (2) were symptoms possibly attributable to medication use, or (3) were possibly disease-associated symptoms observed in individuals who were treated with such medications. An analysis of longitudinal changes in medication use, cognitive, and neuropsychiatric status could help to distinguish between these possibilities.
The most significant limitation of this study was our inability to determine causality between neuropsychiatric symptoms and medication use because of the cross-sectional nature of the analysis. Future study of the longitudinal data available for a subset of this cohort will be necessary to determine the reasons for medication use.
In conclusion, psychiatric medications are commonly used off label in FTD and AD but despite their frequent use, many distressing behaviors persist in both disorders. In FTD, cognitive medications are also frequently used offlabel with no clear benefit. It is clear that more effective pharmacologic and nonpharmacologic interventions are needed to manage the neuropsychiatric symptoms in dementia, particularly FTD.
